Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02327013 · ClinicalTrials.gov registry record · Phase 2
Investigating the Effect of Vortioxetine in Adult ADHD Patients
A Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
- 15
- Study locations
NCT02327013: Completed Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by H. Lundbeck A/S.
NCT02327013 is a Phase 2 study of Attention Deficit Hyperactivity Disorder that has completed, run by H. Lundbeck A/S. The registered enrollment target is 227 participants, roughly in line with the 214-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target. The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02327013, a Phase 2 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.
Primary Outcome
AISRS: an 18-item scale administered by the investigator. It included 9 items that evaluated symptoms of inattention and 9 items that evaluated symptoms of impulsivity and hyperactivity. Each item was rated from 0 (none) to 3 (severe). AISRS total score was calculated as sum of all the items on the scale and ranged from 0 to 54. A higher score corresponded to a worse severity of ADHD.
Conditions Studied
Interventions
- OTHER Placebo tablet
- DRUG vortioxetine 10 mg tablet
- DRUG vortioxetine 20 mg tablet
Study Locations (15)
California
- US015 - Beverly Hills
- US002 - Garden Grove
- US004 - National City
Florida
- US013 - Bradenton
- US006 - Gainesville
New York
- US005 - New York
- US008 - New York
Georgia
- US010 - Alpharetta
Illinois
- US014 - Libertyville
Maryland
- US011 - Baltimore
Massachusetts
- US009 - Boston
Nevada
- US016 - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
What the finished NCT02327013 record still lists
NCT02327013 is an interventional study that assigns participants to a tested intervention. The registered 227 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 214-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo tablet is the first listed.
NCT02327013 lists 15 locations in 11 states (California, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT02327013 about?
NCT02327013 is a clinical study titled "Investigating the Effect of Vortioxetine in Adult ADHD Patients". The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.
What is the current status of trial NCT02327013?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2014-12. Estimated completion is 2016-09.
What conditions does trial NCT02327013 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT02327013?
The interventions under investigation include: Placebo tablet (OTHER), vortioxetine 10 mg tablet (DRUG), vortioxetine 20 mg tablet (DRUG).
Who is sponsoring clinical trial NCT02327013?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02327013 being conducted?
This trial has 15 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02327013's enrollment target sits among peer trials
227 29th of 102 higher than 74 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Stimulant Medication in College Students With ADHD
RECRUITING · Phase 2
-
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
RECRUITING · Phase 2
-
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
COMPLETED · Phase 2
-
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04751409 · 227 participants · Phase 2
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
- NCT05742360 · 227 participants
Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype
- NCT05890352 · 227 participants · Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia